NAARDEN, the Netherlands and MIAMI, Might 01, 2026 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Firm N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, medical biopharmaceutical firm growing oral, non-statin medicines for sufferers liable to heart problems (“CVD”) with elevated low-density lipoprotein ldl cholesterol (“LDL-C”), for whom present therapies will not be sufficiently efficient or well-tolerated, at present introduced that the Compensation Committee of NewAmsterdam’s Board of Administrators authorised the grant of inducement share choices masking an mixture of fifty,400 of NewAmsterdam’s atypical shares to 5 non-executive new hires. The share choices had been granted as an inducement materials to the workers’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Firm N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Itemizing Rule 5635(c)(4).
The share choices have an train value per share equal to $28.43, which represents the closing market value on the Nasdaq Inventory Market of the Firm’s atypical shares on Might 1, 2026, the grant date. The shares topic to the choices will vest over 4 years, with 25% of the shares vesting on the one-year anniversary of the relevant vesting graduation date and the steadiness of the shares vesting in a sequence of 36 equal month-to-month installments thereafter, topic to every worker’s continued service with NewAmsterdam on such vesting dates. The choices are topic to the phrases and situations of the 2024 Inducement Plan and the phrases and situations of an choice award settlement masking the grant.
The Compensation Committee of NewAmsterdam’s Board of Administrators additionally authorised the grant of restricted inventory items masking an mixture of 15,400 of NewAmsterdam’s atypical shares to 5 non-executive new hires. The restricted inventory items had been granted as an inducement materials to the workers’ acceptance of employment with NewAmsterdam pursuant to the 2024 Inducement Plan and in accordance with Nasdaq Itemizing Rule 5635(c)(4).
The restricted inventory items had been granted on Might 1, 2026. The restricted inventory items will vest over three years, with one-third of the restricted inventory items vesting on every of the one-year, two-year and three-year anniversaries of the relevant vesting graduation date, topic to every worker’s continued service with NewAmsterdam on such vesting dates. The restricted inventory items are topic to the phrases and situations of the 2024 Inducement Plan and the phrases and situations of a restricted inventory unit award settlement masking the grant.
About NewAmsterdamNewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical firm whose mission is to enhance affected person care in populations with metabolic illnesses the place presently authorised therapies haven’t been enough or properly tolerated. We search to fill a big unmet want for a protected, well-tolerated and handy LDL-lowering remedy. In a number of section 3 research, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose mixture with ezetimibe, as LDL-C reducing therapies for use as an adjunct to statin remedy for sufferers liable to CVD with elevated LDL-C, for whom present therapies will not be sufficiently efficient or properly tolerated.
More Read
